Kornimate/medical-research-clean huggingface dataset:
healing touch in treating fatigue in women undergoing radiation therapy for breast cancer

Conditions: Breast Cancer; Depression; Fatigue

Summary: rationale: healing touch therapy may be effective in lessening fatigue in women with breast cancer who are undergoing radiation therapy. purpose: this randomized clinical trial is studying how well healing touch works in treating fatigue in women undergoing radiation therapy for breast cancer.

objectives: * to determine the ability to recruit and retain patients with breast cancer receiving curative radiotherapy in a complementary and alternative medicine trial. * to determine the acceptability of weekly healing touch therapy to patients with breast cancer who receive curative radiotherapy. * to examine the effect of healing touch on fatigue and quality of life for patients with breast cancer receiving radiotherapy as a component of therapy. outline: patients are stratified by type of treatment (radiotherapy alone vs chemotherapy completed prior to radiotherapy) * arm i:patients receive healing-touch therapy administered once a week for 45 minutes by a healing-touch therapist for the duration of radiotherapy. * arm ii: patients receive sham-therapy administered once a week for 45 minutes by a sham-practitioner (not a healing-touch therapist) for the duration of radiotherapy. patients complete the hospital anxiety and depression scale (had) and a demographic variables form (age, race/ethnicity, marital status, employment) at baseline. patient fatigue is measured on a weekly basis throughout radiotherapy with completion of the brief fatigue inventory (bfi). the functional assessment of cancer therapy-breast form (fact-b) is completed at baseline and the end of radiotherapy. patients undergo a 20-minute interview at the end of study to determine the acceptability of the intervention.

Eligibility criteria:
inclusion criteria: * histologically proven breast cancer * receiving post lumpectomy or post mastectomy radiation therapy (rt) * eastern cooperative oncology group performance status of 0, 1 or 2 * prescribed a minimum of 5 weeks of rt * between the ages of 21 and 75 * able to speak english. * provides written informed consent exclusion criteria: * documented active psychiatric illness * documented cognitive impairment that would preclude the ability to provide informed consent. * stage iv breast cancer * receiving concurrent chemotherapy and rt

Keywords: fatigue depression psychosocial effects of cancer and its treatment stage i breast cancer stage ii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer recurrent breast cancer
does personality predict patient adherence, health behaviors, and weight loss outcomes during the latino crossover semaglutide study (lcss)? (story-lcss project)

Conditions: Obesity; Body Weight Changes

Summary: the goal of this observational study is to learn about the personality attributes and values of people living with obesity that are part of the latino community, and how these personality attributes and values can help to predict success during a weight loss program. the main questions it aims to answer are: * what are the personality attributes and values of people living with obesity that sign up to the lcss-latino crossover semaglutide study trial? * can behavioral artificial intelligence (a computer formula) predict which patients will complete the lcss-latino crossover semaglutide study trial? * how do behavioral artificial intelligence predictions (a computer formula) compare to clinician predictions of patient success? * can behavioral artificial intelligence (a computer formula) predict patient weight loss, calorie consumption and physical activity levels during the lcss-latino crossover semaglutide study trial? participants will be recorded in english and spanish while responding to a question regarding participation in a weight loss study.


Eligibility criteria:
inclusion criteria: * participation in the lcss-latino crossover semaglutide study exclusion criteria: * not a participant of the lcss-latino crossover semaglutide study at the point of data collection

Keywords: artificial intelligence obesity weight loss
effect of rabies immunoglobulin on immunogenicity of post-exposure rabies vaccination in obese patients

Conditions: Rabies

Summary: a single center, prospective cohort, open-label study of rabies post exposure program with equine rabies immunoglobulin (erig) and purified chick-embryo cell (pcec) rabies vaccine in who category iii exposed patients at siriraj hospital, thailand aims to compare serum rvna responses between obese (bmi \> 30 kg/m2) and normal weight/underweight (bmi \< 25 kg/m2) and to evaluate adverse events occurring after immunization on days 7, 14 and 28.

a single center, prospective cohort, open-label study of rabies post exposure program with equine rabies immunoglobulin (erig) and purified chick-embryo cell (pcec) rabies vaccine in who category iii exposed patients at siriraj hospital, thailand aims to compare serum rvna responses between obese (bmi \> 30 kg/m2) and normal weight/underweight (bmi \< 25 kg/m2) and to evaluate adverse events occurring after immunization on days 7, 14 and 28.

Eligibility criteria:
inclusion criteria: 1. male or female ages of \>= 18 years and older; 2. experienced who category iii rabies exposure excluding presenting wound at eye(s) or eye lid(s); 3. either a) obese with bmi \>= 30 or b) normal weight and/or underweight with bmi \< 25; 4. agree to independently consent to participate in all study procedures. exclusion criteria: 1. positive skin test to erig or known hypersensitivity to erig or its excipients; 2. co-enrolment with other studies or participated in other investigational drug studies or use of other investigational drugs within 4 weeks or five times the half-life of the investigational drug; 3. female patients who are currently pregnant or breast feeding. 4. presenting with wound at eye(s) or eye lid(s); 5. receiving rabies vaccination more than 7 days for this exposure; 6. history of complete pre-exposure or post-exposure regimen with at least 3 doses; 7. known of allergic to egg or poultry meat; 8. history of previous exposure to equine sera 9. significant illness that might harm or increase the risk to the patients; 10. history of drug abuse or alcoholism.

Keywords: rabies obese immunoglobulin rabies vaccine post-exposure immunogenicity
objectives and measures dimensions nasal resistance of preterm and term (modern)

Conditions: Nose Deformities, Acquired

Summary: during the resuscitation of preterm infants, withdrawal of non-invasive ventilation is difficult. in a recent study in children gestational age \<30 weeks of amenorrhea (sa), definitive withdrawal rate from the first attempt to stop the non-invasive ventilation was 32% . in the same study, the median number of attempts before achieving a final withdrawal was 3 for children born before 28 weeks. the reasons for weaning failure are multiple and little studied. it seems that the type of interface used, mask or cannula, having an influence on the effectiveness of non-invasive ventilation . the nasal lesions induced by non-invasive ventilation are not uncommon, regardless of the interface used . in a recent randomized trial, they ranged from 40% to 50% depending on the type of nasal cannula and non-invasive ventilation mode. it is in this case external damage. but we assume that the breakdown causes internal lesions dependent on the pressure, humidity and flow. these factors are likely to generate a nasal obstruction, source intervention nurses who aspire nasal passages more or less traumatic. the nasal cavities are often abused and, because of their key role in breathing, could be involved in the withdrawal of ventilatory failure

the measurements of the nasal cavity dimensions are carried out by acoustic rhinometry (about 10 seconds for an acquisition). measurement of nasal resistance is performed by rhinomanometry earlier (about a minute to a measure). they may be made to wakefulness or sleep since they do not require their participation. these measures will be carried at birth and then every 7 to 10 days (before the age of 28 days), if the child is still hospitalized. during these measurements, the heart rate and oxygen saturation are collected by a measuring sensor transcutaneously.

Eligibility criteria:
inclusion criteria: * affiliation to social security * informed parental consent * newborns term and preterm * age less than or equal to 28 days * signature of informed consent by both parents exclusion criteria: * craniofacial malformation * dyspnea (silverman score\> 3) * severe sepsis * life-threatened
post market clinical follow-up keriflex®

Conditions: Rheumatoid Arthritis; Degenerative Arthritis; Traumatic Arthritis

Summary: the general objective of this study is to assess the performance and safety of the keriflex® silicone joint implant and its associated instruments, used in accordance with the labeling and instructions in force. the performance and safety of the keriflex® joint implant will be established in the short and long term with regard to the life cycle of the implant.


Eligibility criteria:
inclusion criteria: * adult patients (age ≥ 18 years) * patients who are going to undergo arthroplasty of the metacarpophalangeal or proximal interphalangeal joint using a keriflex® implant in accordance with the instructions for use and the labelling in force. * patients with rheumatoid arthritis, osteoarthritis or post-traumatic osteoarthritis exclusion criteria: * pregnant or breastfeeding women * patients with an intellectual disability who cannot follow their surgeon's instructions * patients with general surgery contraindications and particularly to the implantation of a keriflex® implant * patients with acute or chronic, local or systemic infections * metacarpal or phalanx destruction or poor bone quality preventing adequate fixation * muscle loss, alteration or vascular deficiency in the affected finger * patients with significant physical activity involving treated joint * children, young growing patients with open epiphyses
lifestyle intervention for women with recent pre-eclampsia or gestational diabetes mellitus ('mom's healthy heart')

Conditions: Pre-Eclampsia; Gestational Diabetes

Summary: the aim of this pilot intervention study is to develop and test a tailored web-based lifestyle modification program for women with recent preeclampsia or gestational diabetes. women will start the study 3-15 months postpartum. after obtaining written informed consent and confirmation of eligibility criteria, eligible women will be included in the pilot study using a single arm study design (all women will be assigned to the lifestyle intervention program). participants will be provided access to a web-based lifestyle intervention program with personalized coaching from a registered dietician.


Eligibility criteria:
inclusion criteria: * diagnosis of preeclampsia or gestational diabetes in recent pregnancy, confirmed by medical record review * capable to speak and read norwegian * access to internet enabled mobile devices that use either ios or android operating systems exclusion criteria: * diagnosis of chronic hypertension or diabetes mellitus * current use of blood pressure lowering medication * medication known to affect glucose tolerance * active self-reported eating disorder * history of heart disease, stroke or kidney disease * history of gastric bypass or bowel surgery resulting in malabsorption * active medical problems that would interfere with following the diet, or with changes in blood pressure and/or weight

Keywords: mentoring healthy life style postpartum period
microvascular flow and reactivity in patients presenting in the acute phase of covid-19.

Conditions: Coronavirus Infection; Endothelial Dysfunction; Microvascular Rarefaction

Summary: considering that the intensity of systemic microvascular changes in patients in the acute phase of covid-19 could be related to disease progression and prognosis, the present cross-sectional and observational study aims to investigate the presence of endothelial dysfunction in these patients, also looking for to evaluate associations between the presence of endothelial dysfunction and demographic, clinical and laboratory variables.

an association between the presence of previous cardiovascular disease and adverse prognosis has been demonstrated in patients with covid-19 (coronavirus disease-19), presenting increases of up to 5-10 times in mortality. as an initial process, the sars-cov-2 virus, anchored in the transmembrane angiotensin-converting enzyme 2 (eca2), penetrates host cells, including endothelial cells, pericytes and macrophages, in addition to type ii pneumocytes. cellular invasion results in massive release of several pro-inflammatory cytokines ("cytokine storm"), such as il-1β, ifn-1 and il-6, by the cells of the immune system. in turn, cytokines increase the process of vascular inflammation and the expression of leukocyte-vascular endothelium adhesion proteins, which results in endothelial activation accompanied by a pro-coagulant and pro-adhesive phenotype - between leukocytes, platelets, red blood cells and vascular endothelium - characteristic of the dysfunctional endothelium in the microcirculation, which results in severe changes in the microvascular flow and, as a result, in tissue perfusion. it is also worth noting that the patients most vulnerable to the development of complications are those with pre-existing endothelial dysfunction, associated with several risk factors such as male gender and smoking, and comorbidities such as hypertension, diabetes and obesity, all of which are associated with poor prognosis in covid -19. considering that the intensity of systemic microvascular changes in patients in the acute phase of covid-19 could be related to disease progression and prognosis, the present cross-sectional and observational study aims to investigate the presence of endothelial dysfunction in these patients, also evaluating associations between the presence of endothelial dysfunction and demographic, clinical and laboratory variables.

Eligibility criteria:
* age\> 18 years admitted to the hospital * sars-cov-2 positive real-time pcr molecular test exclusion criteria: * presence of non-covid infection with systemic and microbiologically documented repercussions.
treat-be study (treatment with resection and endoscopic ablation techniques for barrett's esophagus)

Conditions: Barrett's Esophagus; Esophageal Cancer

Summary: a prospective outcomes study in patients with and esophageal cancer (eac) and barrett's esophagus (be) associated neoplasia being evaluated for endoscopic eradication therapy (eet).

patients will be enrolled in this study at the participating centers when evaluated in gastro-intestinal (gi) clinics and endoscopy suites. initial evaluation of patients will include collection of data on demographics, assessment of risk factors such as smoking, metabolic syndrome, family history and detailed medication history, and past surgical history. all patients will be complete questionnaires regarding gastroesophageal reflux disease (gerd) symptoms, gerd related quality of life (qol) and overall health related qol. details of all previous endoscopic and surgical evaluation along with histopathology data will be documented. patients undergoing endoscopic evaluation at the participating centers will have their endoscopic and histopathology results documented. this will include data collection regarding use of advanced imaging techniques, details regarding tissue acquisition, eet and adverse events. patients undergoing esophagectomy will have surgical details documented along with complications related to surgery. similarly, details regarding chemoradiation treatments will be documented .

Eligibility criteria:
inclusion criteria: * patients with barrett's related neoplasia and dysplasia. patients with esophageal cancer exclusion criteria: * patients with squamous cell carcinoma
intra-anally administered artesunate in patients with high-grade anal intraepithelial neoplasia (ain 2/3)

Conditions: HPV-Related Anal Intraepithelial Neoplasia; AIN2/3; Artesunate; Alternative Treatment; Anal Dysplasia; Precancerous Conditions; Human Papilloma Virus

Summary: this open label study investigates a novel non-surgical approach to the treatment of hpv-associated anal intraepithelial neoplasia, using artesunate suppositories.

patients diagnosed with ain 2/3 will be enrolled sequentially in treatment cohorts receiving different doses of artesunate suppositories administered trans-anally. doses of escalation will be 200 mg, 400 mg, and 600 mg. treatment cohorts will consist of 2 or 3 cycles at each dose level. suppositories will be administered daily for 5 days. five days constitutes 1 cycle. up to 3 cycles will be administered at weeks 0, 2, and 4.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * biopsy-confirmed high-grade anal dysplasia (ain 2, ain 3, hsil) by high resolution anoscopy (hra) * female of childbearing potential: negative urine pregnancy test * able to provide informed consent * patients who have the ability to collaborate with planned follow-up (transportation, compliance history, etc.). * weight ≥50 kg. exclusion criteria: * diagnosis of low-grade anal dysplasia (ain 1, lsil) by high resolution anoscopy * known anal, vulvar, cervical, or penile cancer * cd4 count \< 200 at the time of consideration for entry into this study * unable to provide informed consent * currently receiving systemic chemotherapy or radiation therapy for another cancer. * patients who are on medical treatment with systemic immunosuppressants or steroids (e.g., active autoimmune disease) * extensive anal condyloma precludes the ability for the clinician to visualize hsil during hra

Keywords: hpv suppository artesunate artemisinin anal dysplasia treatment alternative treatment anal precancer johns hopkins sandy fang frantz viral therapeutics wisconsin evie carchman
optimizing mastitis identification and treatment

Conditions: Mastitis Postpartum

Summary: the goal of this observational study is to gain more information about the aetiology and progression of mastitis and breast inflammation, in order to develop evidence-based clinical guidelines and treatment plans, especially concerning judicious use of antibiotics. the main questions it aims to answer are: * do clinical symptoms differ between inflammatory and infectious mastitis? * what is the microbial composition in human milk, and does it change before, during, and after episodes of mastitis? * does the bacterial composition change due to antibiotic treatment? * are all mastitis episodes treated with antibiotics bacterial mastitis? * do mothers with recurrent mastitis have a distinct microbial composition? * are there immunological markers that can differentiate between bacterial and inflammatory mastitis? researchers will compare breastfeeding women with and without mastitis to see if the microbiological composition in milk and on the skin of the breast and breast nipple differs.

mastitis (breast inflammation) is experienced by up to one-fifth of all breastfeeding mothers. mastitis is a painful condition and a leading cause of early weaning, an undesired outcome with potentially negative implications for both mother and baby. empirical evidence explaining the aetiology of mastitis is lacking; thus the definitions and treatment of mastitis is conflicting. the recent mechanobiological model proposes that the mechanical forces of lactation, especially at the onset of milk production, can cause damage to the mammary tissue, which induces an inflammatory response. concurrently a growing amount of evidence shows that bacteria previously written off as contaminants have a role in mastitis which has been overlooked. the dynamics between the mechanobiological model and bacterial colonization have not yet been investigated. to fill this knowledge gap, researchers will conduct a longitudinal study collecting milk samples and questionnaires during the breastfeeding period with a particular emphasis on mastitis. milk and skin swab samples will be used for culture dependent and culture independent assessment of the microbial composition in mastitis, and will be compared to the composition found in mothers without mastitis. the main objective of this clinical study is to gather empirical data to provide an evidence-based update to the clinical guidelines for mastitis diagnosis and care. this will provide a foundation for improving the treatment and prevention of mastitis, with better outcomes for mothers and newborns.

Eligibility criteria:
inclusion criteria: * pregnant mothers aged \> 18 * mothers must understand information given in norwegian or english * participants must be willing to complete study questionnaires * participants must be willing to and provide biological samples exclusion criteria: * no exclusion criteria

Keywords: breast inflammation clinical mastitis sub-clinical mastitis
navigating the clinical trial process for hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: clinical trials can sometimes favor certain demographic groups. additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative. the goal is to identify the obstacles and challenges that prevent participation in hepatocellular carcinoma clinical research, as well as the reasons for withdrawal or discontinuation. insights gained from this study will ultimately benefit those with hepatocellular carcinoma who may be invited to participate in clinical research in the years to come.


Eligibility criteria:
inclusion criteria: * diagnosed with hepatocellular carcinoma * willing to comply with all study related procedures and assessments * capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (icf) and in the protocol exclusion criteria: * no documented diagnosis of hepatocellular carcinoma * any serious and/or unstable pre-existing medical disorders * pregnant or lactating woman

Keywords: hepatocellular carcinoma